Supplementary Figure 2:
Synthesis route of disaccharide compound ACL19378. i) Ethylene diamine, n-butanol, 120 °C, 40 min. ii) 3,4-dichlorophenyl isocyanate (1.2 eq) in DMF, 3 h iii) Zn, NH4Cl, H2O, MeOH, o/n iv) 3-([1,1'-biphenyl]-4-yl)-3-((tert-butoxycarbonyl)amino)propanoic acid (1.25 eq), HBTU (1.25 eq), DIPEA (4.2 eq), DMF, o/n v) 5% TFA, 15% TES in DCM, 5 h vi) Boc2O (2 eq), H2O, NaHCO3 (pH [7] [8] , o/n vii) sat. NH3, MeOH, 55 °C, 5 h viii) 4-(trifluoromethoxy)phenyl isocyanate (1.2 eq) in DMF, o/n ix) 5% TFA, 15% TES in DCM, 2 h ×) sat. NH3, MeOH.
Supplementary Figure 3:
Representative compounds from disaccharide library (Chemotype D1).
Supplementary Figure 4: (+)-ESI-QToF MS/MS data of ACL19378
The spectra is showing the fragmentation into the two saccharide units, shown with the structure Supplementary Table 1 ACL20219  >128  -----ACL20220  1  1  4  4  1  >64   ACL20962  16  16  16  >64  32  >64   ACL20963  4  8  4  8  8  16   ACL20964  4  8  2  2  8  32   ACL20965  8  8  8  8  8  16   ACL20966  >128  -----ACL20967  8  16  8  32  8  16 Supplementary ) with significant differences in the conformation of helix 4 and the binding site loop (see green and yellow structure in Supplementary Figure 25 ) The only differences are that one has been crystallized in a trigonal and the other in an orthorhombic space group, and the former is an active site mutant E100Q, however both structures show moenomycin in the same binding orientation.
Supplementary

Supplementary Tables
Virtual docking
The crystal structures with moenomycin A locates moenomycin in the donor binding site constituting the growing polysaccharide chain 3, 8 , with the N-Ac group of ring F close to the catalytic site residue Glu100 (numbering by MGT from S. aureus). The virtual docking experiments using the 'best' receptor model 3HZSm (MGT from S. aureus), shows similar overall binding for both ACL20215 and ACL20964, but with different orientations of their benzimidazole groups. ACL20215 has its benzimidazole group close to site occupied by ring F of moenomycin, with the benzyl group along the donor site (occupied by ring E), pointing the trifluoro benzyl group towards the acceptor binding site. For ACL20964, the benzimidazole group is still close to site occupied by ring F of moenomycin, but the naphthyl group is orientated towards the acceptor site, while the trifluoro benzyl group towards the donor site. Even though the orientation of both inhibitor is switched around, their binding orientation is dominated by the three hydrophobic groups: trifluoro benzyl group, benzimidazole, and benzyl or naphthyl group.
One located at the donor site (similar to ring E), one oriented towards the membrane (similar to portion G of moenomycin) and one orientated towards the acceptor site. This last interaction site is not occupied by moenomycin itself.
Conformation of Inhibitors
The compounds with benzimidazole (ACL20215 and ACL20964) exist as atropisomer 13 , conformational isomers, due to the bulkiness of the benzimidazole group in vicinity to the carbohydrate ring, restricting the rotation of the benzimidazole linkage bond to the carbohydrate scaffold. An energy barrier of around 25 kcal mol -1 for this bond which -in relation to other known atropisomerscorresponds to an interconversion rate of a few hours and up to few days 14 . This corroborates our observations that while two isomers could be detected in the NMR experiment, they could not be separated using chromatography.
Supplementary Methods
Conformational (rotamer) search of ACL20215
Both monosaccharide compounds showed distinct conformations in the ).
Hemolysis assay
Human male red blood cells were isolated from fresh whole blood sample and washed with phosphate buffered saline (PBS) 3 times. Red blood cells were diluted 1/200 with PBS for the haemolysis assay.
Each compound was assayed at 4 different concentrations in quadruplicate. Control items (100 μM tamoxifen and 1% triton X100) were also assayed in quadruplicate. Background was determined with 1% DMF. The assay was performed for 1 h at 37 °C. The samples were then centrifuged for 10 min at 4°C at 1000 × g, the supernatant was recovered and absorption was measured at 415 nm. Results are expressed as the % haemolysis compared to 1% triton X100 after background was subtracted, and fitting dose response curve with Prism (GraphPad) to extract HC50 values.
Bacterial Cytoplasmic Membrane Permeability Assay
The depolarization of the cytoplasmic membrane of S. aureus (ATCC25923) caused by the antibiotics was determined using the membrane potential-sensitive cyanine dye diSC35 and using the method described by Wu et al. 15 with some modification. Briefly, the overnight subcultures of bacteria were grown in LB broth at 37 °C with shaking to mid-logarithmic phase (OD600 = 0.5 to 0.6). Cells were collected by centrifugation at 5,000 × g for 10 min, washed once with the buffer (5 mM HEPES, pH 7. 
where Fm is the maximal fluorescence increase after the addition of a compound at a particular concentration; Fi is the initial fluorescence (the fluorescence level of cell suspension just after the addition of compound) and Fb is the fluorescence of blank. Citropin 1.1, which is known to disrupt membrane integrity of bacteria, was used as a positive control (100%) at a concentration of 32 µg mL -1 in this study [16] [17] [18] .
Inhibition of Lipid II and peptidoglycan biosynthesis
The cell-free particulate fraction of Bacillus megaterium KM (ATCC13632), capable of catalysing the polymerisation of PG from UPD-linked precursors was performed as described previously 19 . Then the bacteria were subjected to three freeze/thaw cycles (dry ice for 5 min followed by RT for 10 min). After the freeze/thaw cycles, bacteria were homogenized by using the glass homogenizer at 4 °C (10 min × 2).
The broken cell suspension was centrifuged at 6,000 x g for 10 min at 4 °C. The supernatant which contained the unbroken cells and the majority of the cell walls was kept for further centrifugation. The pellet was resuspended in the same buffer and re-centrifuged at 6000 x g for 10 min at 4 °C, and the supernatant was kept for further centrifugation. The two supernatants were combined and 
Glycosyltransferase activity by HPLC
A solution containing NBD-lipid II (4 µM) in buffer (50 mM Tris, pH 8.0, 10 mM CaCl2, 0.085% Decyl PEG50, 10% DMSO, 15% MeOH) containing 10 µg µL -1 N-acetylmuramidase was mixed at 1000 rpm at 25 °C. The reaction was initiated by addition of glycosyltransferease (2.5 µg mL The results with PBP1 from C. difficile showed some inhibition for ACL20215, while the experiment with ACL20964 displays no detection of either the substrate (NBD-lipid II) or the product of the glysyltransferase reaction (marked in Supplementary Figure 23 with 'Strange behaviour'). However the experiment with MGT A from S. aureus shows some inhibitory effect for both the compounds. These preliminary results were used to optimise the experiment to extend it to a dose response assay.
In vitro metabolic stability studies
Compounds (1 μM) were incubated at 37 °C with human or mouse liver microsomes. The reaction was initiated by the addition of an NADPH-regenerating system and quenched at various time points over the incubation period by the addition of acetonitrile. Additional samples co-activated by NADP and UDPGA (the co-factor for glucuronidation), were included in the incubation for the qualitative assessment of the potential for glucuronide formation. The relative loss of parent compound and formation of metabolic products was determined by LC/MS using the Q-TOF instrument. The studies were conducted by a contract research organization (Centre for Drug Candidate Organization, Monash University, Melbourne, Australia).
In vivo efficacy and PK studies
The in vivo pharmacokinetics of the compounds were studies in overnight-fasted male Sprague Dawley rats weighing 328-334 g. Rats had access to water ad libitum throughout the pre-and post-dose sampling period, and access to food was re-instated 4 hours post-dose. Compounds were administrated IV as a 10 minute constant rate infusion (1.0 mL per rat, n=2 rats). Samples of arterial blood and total urine were collected up to 48 h post-dose. Arterial blood was collected directly into borosilicate vials (at 4 °C) containing heparin, Complete (a protease inhibitor cocktail), potassium fluoride and EDTA to minimize potential for ex vivo degradation. Once collected, blood samples were centrifuged, supernatant plasma was removed, and plasma concentration of compounds were determined by LCMS (LLQ 0.0014 M). The studies were conducted by a contract research organization (Centre for Drug Candidate Organization, Monash University, Melbourne, Australia).
In vivo Maximum Tolerated Dose
Compound dissolved in 0.05% Tween 80/0.9% NaCl were each administered IP at doses of 20, 60 and 100 mg kg -1 to groups of 2 CD-1 (Crl.) derived male mice weighing 22 ± 2 g. The animals were observed for presence of acute toxic symptoms (mortality, convulsions, tremors, muscle relaxation, sedation, etc.) and autonomic effects (diarrhea, salivation, lacrimation, vasodilation, piloerection, etc.) during the first 30 min post-dosing. Any occurrence of mortality was noted at 3, 24, 48 and 72 h after treatment.
For the IV studies, compounds were dissolved in 10% DMSO/0.1 M HCl/1% Tween 80/5% Glucose were prepared at a dose of 4 mg kg -1 and were administered intravenously once to groups of 3 CD-1 (Crl.) derived male mice weighing 22 ± 2 g, and monitored and analyzed similar to the IP study during the first 5 min post dosing (IV). In addition, Group 3 and Group 5 were administered intravenously with compounds at 4 mg kg -1 for 2 times (T=0 and T=170 minutes) and the autonomic signs and neurological changes were observed during the first 5 min after the first and the second dose. Mortality was also observed at the subsequent 30 min, 1, 24, 48 and 72 h after test substances treatment. Both studies were conducted by a contract research organization (MDS Pharma Services, Taipei, Taiwan).
In vivo Septicaemia mouse model
Groups of 10 male CD-1 (Crl.) derived mice weighing 22 ± 2 g were used. The mice were inoculated intraperitoneally (IP) with a LD90-100 of Staphylococcus aureus (Smith) (3.7 × 10 5 CFU mouse For the corresponding IV studies compounds at 4 mg kg -1 were dissolved in 10% DMSO/0.1 M HCl/1%
Tween 80/5% glucose, and compounds were each administered intravenously at 10 min and/or 180 min after S. aureus (Smith) challenge.
In vivo Mastitis mouse model
For the infection of the mice S. aureus Newbould 305 (ATCC 29740) was used , which was originally isolated from a clinical mastitis case 21 . Bacterial preparation was previously described 22 . Briefly, an overnight brain heart infusion (BHI; Oxoid Limited) culture of the bacteria was diluted in sterile phosphate-buffered saline (PBS; Gibco) and quantified by flow cytometry (BD biosciences).
Subsequently, 1 ml of a 1000-fold PBS-diluted bacterial suspension was added to a TRUcount tube (BD biosciences), which contained a known number of fluorescent beads. The number of bacteria was then calculated using the following equation:
The actual colony forming units (CFU) of the inocula was confirmed by overnight culture of a serial logarithmic dilution on tryptic soy agar (TSA; Oxoid Limited) plates.
Determination of the MIC of compounds for the experimental bovine mastitis isolate S. aureus
Newbould 305 was performed using the Mueller-Hinton agar dilution assay according to CLSI guidelines 23 . Plates were incubated at 35 °C (+/-2 °C) for 16-20 h in an aerobic atmosphere. In addition the MIC of a random selection of recent bovine mastitis field isolates (10 isolates for each antibiotic) was determined in order to ensure that the sensitivity of the experimental isolate concurred with the sensitivity of a naïve bacterial population encountered in the field.
The procedure for mouse mammary gland infection has been recently described 22 . Briefly, CD-1 lactating mice (Harlan Laboratories Inc.) were utilized 12 to 14 days after birth of the offspring. The pups were weaned 1 to 2 h before bacterial inoculation of the mammary glands. A mixture of oxygen and isoflurane (2-3%) was used for inhalational anaesthesia of the lactating mice. A syringe with 32-gauge blunt needle (Thiebaud biomedical devices) was applied to inoculate both L4 (on the left) and R4 (on the right) glands of the fourth abdominal mammary gland pair with approximately 150 CFU of S. aureus. Each orifice was exposed by a small cut at the near end of the teat and 100 µl of the inoculum was injected slowly through the teat canal. The antimicrobial formulation was instilled into the mammary gland of anesthetised mice using the desired dose (µg gland gland from the control group by 2log10 and 4log10, respectively. The PD50 and PD100 are the doses of antimicrobial needed to observe respectively 50% and 100% of cleared mammary glands, i.e. with CFU g -1 below the detection limit (DL). The equations that fitted best, i.e. yielded the highest R 2 , with the dose-response relationship of the antibiotic are summarised in Supplementary Table 6 . The ED2log10
and ED4log10 values were then computed by calculating 'x' from these equations, in which 'y' is replaced by 'z-2' and 'z-4', respectively, with 'z' being the mean final CFU g -1 from the negative control group.
Design and Synthesis of Disaccharide-Based Library
Synthesis of Disaccharide 2. Disaccharide 1 (2.0 g, 1.89 mmol) was suspended in a mixture of n-butanol (14 ml) and ethylenediamine (14 ml 
Synthesis of Disaccharide 3.
A solution of the crude azido-sugar 2 (2.11 g) in DMF (11.5 ml) was treated with MeOH (2.9 ml), a solution of NH4Cl (770 mg, 14.4 mmol, 10 equiv.) in H2O (1.6 ml) and activated zinc dust (5.65 g, 86.4 mmol, 60 equiv.). The suspension was stirred at room temperature overnight.
Chloroform (15 ml) was added and the suspension was filtered through celite washing with chloroform/DMF (1:1, 60 ml). The combined filtrates were washed with brine (100 ml), dried (MgSO4) and the solvent was removed in vacuo to give the sugar-amine as a white solid, 1.57 g, 100 %. Rt 6.88, in dry DMF (0.2 ml, 0.41 M). The reaction was hand shaken and left to sit in the glove box overnight.
The solvent was removed in vacuo. To the resulting disaccharide (49 mol) was added a solution of TFA (5%), triethylsilane (15%) in dry DCM (4 ml). The reaction was stirred at room temperature for 2 h and the solvent was removed in vacuo. The resulting disaccharide was then dissolved in a solution of saturated ammonia in methanol (3 ml). The reaction mixture was heated at 55 °C for 2 h and the solvent was removed in vacuo to give ACL19378. The crude product was purified by LCMS on standard C18 column using a water/acetonitrile gradient.
Analysis data for ACL19378 (NMR and MS)
MS spectra of ACL19378 were obtained using an AB Sciex TripleTOF® 5600 (ABSCIEX, Canada) equipped with a DuoSpray Ion Source. ACL19378 was infused into the MS system using a Harvard Syringe Pump at 10 µL min .
